Who are Imitrex®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sumatriptan Succinate Oral Tablet, naratriptan HCl, Placebo to rizatriptan tablets, Comparator: rizatriptan benzoate, Comparator: sumatriptan, Comparator: Rizatriptan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imitrex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Imitrex® — Competitive Intelligence Brief

Imitrex® (Imitrex®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan (5-HT1B/1D receptor agonist). Area: Neurology.

marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B and 5-HT1D receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Imitrex® (Imitrex®) — Teva Pharmaceuticals USA. Imitrex is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Imitrex® TARGET	Imitrex®	Teva Pharmaceuticals USA	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B and 5-HT1D receptors
Sumatriptan Succinate Oral Tablet	Sumatriptan Succinate Oral Tablet	Damanhour Teaching Hospital	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
naratriptan HCl	naratriptan HCl	Cady, Roger, M.D.	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Placebo to rizatriptan tablets	Placebo to rizatriptan tablets	Merck Sharp & Dohme LLC	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Comparator: rizatriptan benzoate	Comparator: rizatriptan benzoate	Organon and Co	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Comparator: sumatriptan	Comparator: sumatriptan	Organon and Co	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Comparator: Rizatriptan	Comparator: Rizatriptan	Organon and Co	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan (5-HT1B/1D receptor agonist) class)

Organon and Co · 3 drugs in this class
Cady, Roger, M.D. · 1 drug in this class
Damanhour Teaching Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imitrex® — Competitive Intelligence Brief. https://druglandscape.com/ci/imitrex. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab